



US 20210253682A1

(19) **United States**(12) **Patent Application Publication**

Stub Laursen et al.

(10) **Pub. No.: US 2021/0253682 A1**(43) **Pub. Date: Aug. 19, 2021**(54) **SINGLE DOMAIN ANTIBODIES FOR
COMPLEMENT REGULATION**(30) **Foreign Application Priority Data**

Jun. 11, 2018 (EP) 18176954.8

(71) Applicant: **Aarhus Universitet, Aarhus C (DK)****Publication Classification**(72) Inventors: **Nick Stub Laursen, Aarhus C (DK);
Dennis Vestergaard Pedersen, Aarhus
C (DK); Gregers Rom Andersen,
Brabrand (DK); Steffen Thiel, Risskov
(DK); Alessandra Zarantonello,
Aarhus C (DK); Rasmus Kjeldsen
Jensen, Aarhus C (DK); Henrik
Pedersen, Aarhus C (DK)**(51) **Int. Cl.**
C07K 16/18 (2006.01)
A61P 35/00 (2006.01)
(52) **U.S. Cl.**
CPC **C07K 16/18** (2013.01); **A61P 35/00**
(2018.01); **C07K 2317/569** (2013.01); **C07K**
2317/92 (2013.01); **C07K 2317/31** (2013.01);
C07K 2317/565 (2013.01); **C07K 2317/33**
(2013.01); **C07K 2317/34** (2013.01)(73) Assignee: **Aarhus Universitet, Aarhus C (DK)**(57) **ABSTRACT**

Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well as methods of treating disorders associated with complement activation.

(21) Appl. No.: **17/251,023**(22) PCT Filed: **Jun. 11, 2019**(86) PCT No.: **PCT/EP2019/065206**

§ 371 (c)(1),

(2) Date: **Dec. 10, 2020****Specification includes a Sequence Listing.**